Tags

Type your tag names separated by a space and hit enter

[Cardiometabolic effects of rimonabant in obese/overweight subjects with dyslipidaemia or type 2 diabetes].
Rev Med Liege. 2007 Feb; 62(2):81-5.RM

Abstract

Rimonabant (Acomplia) is the first selective CB1 receptor blocker of the endocannabinoid system. It has been evaluated in the RIO ("Rimonabant In Obesity and related disorders") programme including above 6.600 overweight/obese patients with or without comorbidities followed for 1 to 2 years. Compared to placebo, rimonabant 20 mg/day consistently increases weight loss, reduces waist circumference, increases HDL cholesterol, lowers triglyceride levels, diminishes insulin resistance, and reduces the prevalence of metabolic syndrome. In patients with type 2 diabetes, rimonabant also diminishes HbA1c levels, an effect confirmed in the recent SERENADE trial. Almost half of the metabolic effects occurs beyond weight loss, suggesting direct peripheral effects of rimonabant. Rimonabant is indicated in Europe as an adjunct to diet and exercise for the treatment of obese patients, or overweight patients with associated risk factor(s), such as type 2 diabetes or dyslipidaemia.

Authors+Show Affiliations

Service de Diabétologie, Nutrition et Maladies métaboliques, CHU Sart Tilman, Liège, Belgique.No affiliation info available

Pub Type(s)

Clinical Trial, Phase III
Comparative Study
Journal Article
Meta-Analysis
Randomized Controlled Trial

Language

fre

PubMed ID

17461296

Citation

Scheen, A J., and L F. Van Gaal. "[Cardiometabolic Effects of Rimonabant in Obese/overweight Subjects With Dyslipidaemia or Type 2 Diabetes]." Revue Medicale De Liege, vol. 62, no. 2, 2007, pp. 81-5.
Scheen AJ, Van Gaal LF. [Cardiometabolic effects of rimonabant in obese/overweight subjects with dyslipidaemia or type 2 diabetes]. Rev Med Liege. 2007;62(2):81-5.
Scheen, A. J., & Van Gaal, L. F. (2007). [Cardiometabolic effects of rimonabant in obese/overweight subjects with dyslipidaemia or type 2 diabetes]. Revue Medicale De Liege, 62(2), 81-5.
Scheen AJ, Van Gaal LF. [Cardiometabolic Effects of Rimonabant in Obese/overweight Subjects With Dyslipidaemia or Type 2 Diabetes]. Rev Med Liege. 2007;62(2):81-5. PubMed PMID: 17461296.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Cardiometabolic effects of rimonabant in obese/overweight subjects with dyslipidaemia or type 2 diabetes]. AU - Scheen,A J, AU - Van Gaal,L F, PY - 2007/4/28/pubmed PY - 2007/6/6/medline PY - 2007/4/28/entrez SP - 81 EP - 5 JF - Revue medicale de Liege JO - Rev Med Liege VL - 62 IS - 2 N2 - Rimonabant (Acomplia) is the first selective CB1 receptor blocker of the endocannabinoid system. It has been evaluated in the RIO ("Rimonabant In Obesity and related disorders") programme including above 6.600 overweight/obese patients with or without comorbidities followed for 1 to 2 years. Compared to placebo, rimonabant 20 mg/day consistently increases weight loss, reduces waist circumference, increases HDL cholesterol, lowers triglyceride levels, diminishes insulin resistance, and reduces the prevalence of metabolic syndrome. In patients with type 2 diabetes, rimonabant also diminishes HbA1c levels, an effect confirmed in the recent SERENADE trial. Almost half of the metabolic effects occurs beyond weight loss, suggesting direct peripheral effects of rimonabant. Rimonabant is indicated in Europe as an adjunct to diet and exercise for the treatment of obese patients, or overweight patients with associated risk factor(s), such as type 2 diabetes or dyslipidaemia. SN - 0370-629X UR - https://www.unboundmedicine.com/medline/citation/17461296/[Cardiometabolic_effects_of_rimonabant_in_obese/overweight_subjects_with_dyslipidaemia_or_type_2_diabetes]_ L2 - https://www.rmlg.ulg.ac.be/aboel.php?num_id=1543&langue=EN DB - PRIME DP - Unbound Medicine ER -